Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 11 1 2016 12 29 58 62 EN Ipek Yonal-Hindilerden Department of Internal Medicine, Division of Hematology, Istanbul University Istanbul Medical Faculty, Istanbul, Turkey Sevgi Kalayoglu-Besisik Department of Internal Medicine, Division of Hematology, Istanbul University Istanbul Medical Faculty, Istanbul, Turkey Nuray Gurses-Koc Department of Internal Medicine, Division of Hematology, Istanbul University Istanbul Medical Faculty, Istanbul, Turkey Fehmi Hindilerden Hematology Clinic, Istanbul Bakırkoy Sadi Konuk Training and Research Hospital, Istanbul, Turkey Deniz Sargin Department of Internal Medicine, Division of Hematology, Istanbul Medipol University, Istanbul, Turkey 2016 01 31 2016 02 25 Background: For adult ALL patients, the indications and appropriate timing of allogeneic hematopoietic stem cell transplantation (AHSCT) continue to be debated. The primary aim of this single-institution study was to compare the results of our adult ALL patients that had been allografted with those reported in the current literature. Subjects and Methods: This study included 53 consecutive adults with acute lymphoblastic leukemia (ALL) who underwent allogeneic hematopoietic stem cell transplantation (AHSCT) with myeloablative (92%) and reduced-intensity (8%) conditioning between 1993 and 2011. Results: Mean patient age was 27 years (SD:8.62) and donor age was 33.7 years (SD:9.47). Fourteen patients were in first remission; 21 in ≥2nd remission, 15 in relapse and 3 had primary refractory leukemia. Thirty-four, 15 and 4 patients received busulfan plus cyclophosphamide, cyclophosphamide/total body irradiation and fludarabine-based regimens, respectively. For graft-versus-host disease (GVHD) prophylaxis, cyclosporine plus methotrexate were used. Forty-six donors were related and 7 were unrelated. Thirty patients received granulocyte-colony stimulating factor (G-CSF) mobilized peripheral blood and 23 received bone marrow as stem cell source. Twenty-six patients relapsed at a mean duration of 11.3 months (SD:19.1). Forty-four patients succumbed to their disease after a mean follow-up of 13.6 months (SD:19.5). The cause of mortality was relapse (n=24; 54.5%) and transplant-related etiologies (n=20; 45.5%). The estimated five year probabilities of overall survival (OS) and progression-free survival (PFS) were 37% and 12%, respectively. Conclusion: By multivariate analyses, transplantation in first remission was the most important predictor of transplant success. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/559 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/559/537